[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulmonary-hypertension\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulmonary-hypertension":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,126,0,25,[9,45,72,96,119,145,173,193,218,250,275,299,322,356,377,402,427,452,476,496,518,555,577,605,621],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100586150","multi-site-study-of-the-clinical-impact-of-an-ai-assisted-approach-to-referring-patients-with-interstitial-lung-disease-for-diagnostic-evaluation-of-pulmonary-hypertension-100586150",false,"NCT06911632","Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension","MOMENTOUS Study (iMpact Of an Ecg ai ModEl oN The Diagnosis Of pUlmonary hypertenSion)","MOMENTOUS","Inclusion Criteria:\n\n* 18 years or older at the time of consent\n* A known diagnosis of interstitial lung disease\n* Diffusing capacity for carbon monoxide (DLCO) \\\u003C30% predicted, collected within 3 months prior to consent\n* Willing and able to provide informed consent and undergo all study-specific procedures, including echo and RHC, if required\n\nExclusion Criteria:\n\n* A known diagnosis of pulmonary hypertension (including patients prescribed a therapy specifically for pulmonary arterial hypertension (PAH))\n* A RHC was completed within the previous 1 year or ordered and not yet completed at the time of consent\n* LV ejection fraction ≤ 40% on most recent echo or cardiac MRI, if available\n* Unclassifiable Tempus PH ECG risk result after up to 2 ECG acquisitions\n* A contraindication to RHC exists (for example, pregnancy or mechanical right heart valve)\n* Physician decision that if a patient is directed to RHC by the study protocol, the potential risks of RHC outweigh the potential benefits\n* There is a severe concomitant illness limiting life expectancy to less than 6 months (at the discretion of the investigator)\n* There is a medical or social factor that makes the patient a poor candidate for the study and\u002For unlikely to be able to comply with the study protocol or complete study procedures (at the discretion of the investigator)","ALL","18 Years",{"count":21,"type":22},900,"ESTIMATED","INTERVENTIONAL",[25],"NA","MOMENTOUS is a multi-center, randomized study to prospectively evaluate the performance of an ECG-based AI device to predict whether participants with interstitial lung disease (ILD) are at high risk of undiagnosed pulmonary hypertension.",[28,29],"Pulmonary Hypertension","Interstitial Lung Disease (ILD)",[28,31],"Interstitial lung disease (ILD)","RECRUITING","2026-06-30",{"date":35,"type":36},"2026-07-02","ACTUAL",{"date":38,"type":36},"2025-07-23",{"date":40,"type":22},"2028-07",{"name":42,"class":43},"Tempus AI","INDUSTRY",30,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":66,"leadSponsor":68,"locationsCount":71},"100643993","correlation-between-ct-pulmonary-angiography-metrics-and-right-heart-catheterization-parameters-in-pre-capillary-pulmonary-hypertension-100643993","NCT07667595","Correlation Between CT Pulmonary Angiography Metrics and Right Heart Catheterization Parameters in Pre-Capillary Pulmonary Hypertension","Inclusion Criteria:\n\n1-Age ≥ 18 years at time of enrolment. 2-Confirmed pre-capillary pulmonary hypertension on RHC performed at Assiut University Hospital: mPAP \\> 20 mmHg AND PAWP ≤ 15 mmHg AND PVR ≥ 2 Wood Units.\n\n3-WHO PH Clinical Group 1 (PAH), Group 3 (PH due to lung disease\u002Fhypoxia), or Group 4 (CTEPH \u002F chronic thromboembolic PH) classification assigned by the PH-MDT.\n\n4-Both CTPA and RHC performed within a maximum interval of 4 weeks. b. Exclusion criteria:\n\n1. WHO PH Group 2 (PH due to left heart disease) or Group 5 (PH with unclear\u002Fmultifactorial mechanisms) .\n2. Active malignancy.\n3. Pregnancy, confirmed or suspected.\n4. Contraindication to iodinated contrast agent: eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m² OR documented history of severe anaphylactic contrast reaction.\n5. Inability to sustain breath-hold of ≥ 8 seconds (impairs CTPA quality).\n6. Initiation or dose escalation of pulmonary vasodilator therapy (endothelin receptor antagonist, PDE5 inhibitor, soluble guanylate cyclase stimulator, or prostanoid) in the interval between CTPA and RHC, or within 4 weeks prior to CTPA.\n7. Patient refusal to consent or inability to provide informed consent",{"count":52,"type":22},60,"OBSERVATIONAL","Pulmonary hypertension (PH) is a hemodynamic and pathophysiological condition defined by a mean pulmonary artery pressure (mPAP) greater than 20 mmHg at rest, as confirmed by right heart catheterization (RHC) (1). The global prevalence of PH is estimated at approximately 1% of the adult population, rising to 10% or more in individuals over 65 years of age.Pre-capillary pulmonary hypertension, which includes pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), is characterized by a pulmonary arterial wedge pressure (PAWP) ≤15 mmHg and an elevated pulmonary vascular resistance (PVR) ≥2 Wood units (2)\n\nComputed tomography pulmonary angiography (CTPA) is routinely performed in the diagnostic workup of PH and offers a non invasive alternative that can generate multiple quantitative metrics from a single scan (3). Traditional CTPA metrics, including main pulmonary artery diameter (MPAd), the ratio of MPAd to ascending aortic diameter, central pulmonary arteries, and right ventricular to left ventricular diameter (RV\u002FLV ratio) were previously studied in PH patients (4,5,6) Most existing studies have evaluated CTPA metrics in isolation or within single PH subgroups, limiting generalizability across the broader pre-capillary PH population (7).\n\nTherefore, this study aims to systematically investigate the correlation between multiple quantitative CTPA metrics and key invasive hemodynamic parameters derived from RHC in patients with confirmed pre-capillary pulmonary hypertension",[28,56,57,58],"Precapillary Pulmonary Hypertension","Right Heart Catheterisation","CT Angiography",[60],"CTPA and RHC in precapillary PHTN","NOT_YET_RECRUITING","2026-06-24",{"date":64,"type":36},"2026-06-25",{"date":33,"type":22},{"date":67,"type":22},"2026-07-30",{"name":69,"class":70},"Assiut University","OTHER",1,{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":80,"enrollmentInfo":81,"targetDuration":83,"studyType":53,"phases":4,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":95},"100526015","an-open-label-prospective-multicenter-study-to-evaluate-safety-and-tolerability-of-dry-powder-inhaled-treprostinil-in-ph-100526015","NCT06129240","An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH","An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in Pulmonary Hypertension","ASCENT","Cohort A Key Inclusion Criteria:\n\n1. Males or Females between 18 years to 80 years of age.\n2. Has a confirmed diagnosis of WHO Group 3 PH-ILD based on CT chest imaging performed, which demonstrates evidence of diffuse parenchymal lung disease and FEV1\u002FFVC (absolute values) ≥ 70% and are required to have evidence of pulmonary hypertension (PH) as demonstrated from right heart catheterization (RHC) with the following hemodynamic parameters.\n\n   1. i) Pulmonary vascular resistance (PVR) ≥ 3 Wood Units (WU) and ii) Pulmonary capillary wedge pressure (PCWP) of ≤ 15 mmHg and iii) A mean pulmonary arterial pressure (mPAP) of ≥ 30 mmHg.\n\n      OR\n   2. An exploratory subset of subjects with ILD: i) Pulmonary vascular resistance (PVR) ≥ 3 Wood Units (WU) and ii) Pulmonary capillary wedge pressure (PCWP) of ≤ 15 mmHg and iii) A mean pulmonary arterial pressure (mPAP) of ≥ 21 mmHg.\n3. 6-minute walk distance of ≥ 125 meters\n\nCohort A Key Exclusion Criteria:\n\nA Subject is not eligible for inclusion in the study if any of the following criteria apply:\n\n1. PH in the Updated WHO Classification Groups 1, 2, 4, or 5.\n2. History of hemodynamically significant left-sided heart disease.\n3. Exacerbation of underlying lung disease or active pulmonary or upper respiratory infections.\n4. Initiation of pulmonary rehabilitation.\n\nCohort B Key Inclusion Criteria\n\n1. Male or Females between 18 years to 75 years of age at Screening.\n2. Has a diagnosis of WHO Group 3 PH-ILD confirmed with CT chest imaging performed at the screening visit, which demonstrates evidence of diffuse parenchymal lung disease and FEV1\u002FFVC (absolute values) ≥70%. Subjects are required to have evidence of pulmonary hypertension (PH) as demonstrated from right heart catheterization (RHC) with the following documented parameters:\n\n   1. Pulmonary vascular resistance (PVR) ≥3 Wood Units (WU) and\n   2. Pulmonary capillary wedge pressure (PCWP) of ≤ 15 mmHg and\n   3. A mean pulmonary arterial pressure (mPAP) of ≥ 25 mmHg\n3. Subjects must be on protocol specified dose of inhaled treprostinil QID not at treatment goal, and able to transition from their prescribed dose of inhaled Treprostinil therapy to LIQ861.\n4. 6-minute walk distance of ≥ 200 meters\n\nCohort B Key Exclusion Criteria\n\n1. PH in the Updated WHO Classification Groups 1, 2, 4, or 5.\n2. Inability to titrate inhaled treprostinil above 5 breaths (Tyvaso®) or above 16 mcg Tyvaso DPI®.\n3. History of Bronchospasm with Tyvaso or Tyvaso DPI.\n4. History of persistent moderate asthma or severe asthma.\n5. History of hemodynamically significant left-sided heart disease.\n6. Exacerbation of underlying lung disease or active pulmonary or upper respiratory infections.","80 Years",{"count":82,"type":22},80,"52 Weeks","Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 \\& 3 PH.",[28,86],"Interstitial Lung Disease",{"date":88,"type":36},"2026-06-26",{"date":90,"type":36},"2023-12-28",{"date":92,"type":22},"2028-02-08",{"name":94,"class":43},"Liquidia Technologies, Inc.",23,{"id":97,"slug":98,"hasResults":12,"nctId":99,"briefTitle":100,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":105,"conditions":106,"keywords":107,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":118},"100642046","pulmonary-hypertension-ph-biorepository-for-translational-research-100642046","NCT07647549","Pulmonary Hypertension (PH) Biorepository for Translational Research","* INCLUSION CRITERIA:\n* Provision of signed and dated informed consent form\n* Males and females aged \\>=18 years old\n* Suspected of or diagnosed with PH\n* Able to understand and willing to sign a written informed consent document\n\nEXCLUSION CRITERIA:\n\nAny individual who does not meet all inclusion criteria or is deemed by the local investigator not to be a blood draw candidate will be excluded from participating in this study.","100 Years",{"count":104,"type":22},1000,"Background:\n\nPulmonary hypertension (PH) is high blood pressure in the blood vessels of the lungs. It can lead to heart failure and death if not treated. Researchers want to create a repository of blood samples and health information collected from people with PH. They hope to use this information to find better ways to diagnose and treat PH.\n\nObjective:\n\nTo collect blood samples and health information from people suspected of or diagnosed with PH.\n\nEligibility:\n\nPeople aged 18 years and older who have or may have PH.\n\nDesign:\n\nResearchers will collect information from participants medical records.\n\nParticipants will have blood drawn from a vein. About 3 tablespoons will be collected during the study visit. The visit will last about 1 hour.\n\nParticipants may choose to provide new blood samples at follow-up visits. Updated medical information may also be collected.\n\nParticipants may continue to participate as long as the study is ongoing. Participants may opt out of providing new blood samples but remain in the study.\n\nAll study samples will be stored at the National Institutes of Health. Health information will be stored in secure databases.",[28],[28,108],"Biorepository","2026-06-23",{"date":62,"type":36},{"date":112,"type":22},"2026-08-03",{"date":114,"type":22},"2036-06-01",{"name":116,"class":117},"National Institutes of Health Clinical Center (CC)","NIH",3,{"id":120,"slug":121,"hasResults":12,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":12,"sex":18,"minAge":126,"maxAge":19,"enrollmentInfo":127,"targetDuration":4,"studyType":23,"phases":128,"briefSummary":129,"conditions":130,"keywords":135,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":138,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":71},"100635707","medlypeds-feasibility-study-100635707","NCT07556185","MedlyPeds Feasibility Study","MedlyPeds Feasibility Study: A Mobile, Smartdevice Based Telemonitoring for Pediatric Heart Disease, a Prospective Cohort Study","Inclusion Criteria:\n\n1. Consent provided.\n2. Aged 8-18 years of age.\n3. Ability to comply with using Medly (ex. able to stand on the weight scale, able to answer symptom questions, etc.)\n4. Followed at the Hospital for Sick Children Cardiology Clinic for any of the following reasons:\n\n   1. Heart failure of any etiology\n   2. Congenital heart disease\n   3. Acquired heart disease (eg. Kawasaki disease, rheumatic heart disease, connective tissue disorders etc)\n   4. Pulmonary hypertension\n   5. Post-cardiac surgery including heart transplant and ventricular assist devices\n\nExclusion Criteria:\n\n1. Unable to read or write in English.\n2. Participating in another clinical trial that may confound the results.\\* \\*Participant may be re-screened for eligibility at a later date.","8 Years",{"count":44,"type":22},[25],"SickKids and UHN have developed MedlyPeds which is a smart phone application designed to remotely monitor patients with heart disease. This is a feasibility study which will enroll up to 30 patients with different types of heart disease to see which patient types may benefit the most from MedlyPeds if it were to be used for clinical monitoring. The study is gathering feedback about the app from patients, parents and clinicians to confirm how it needs to be modified to better serve the purpose in a future trial.",[131,132,133,28,134],"Pediatric Heart Failure","Congenital Heart Disease (CHD)","Acquired Heart Disease","Post Cardiac Surgery",[136,137],"Medly","Telemonitoring",{"date":88,"type":36},{"date":140,"type":22},"2026-07",{"date":142,"type":22},"2029-12",{"name":144,"class":70},"The Hospital for Sick Children",{"id":146,"slug":147,"hasResults":12,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":155,"conditions":156,"keywords":159,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":71},"100643944","multimodality-rv-phenotyping-for-risk-stratification-and-short-term-outcomes-in-group-1-pah-100643944","NCT07667673","Multimodality RV Phenotyping for Risk Stratification and Short-Term Outcomes in Group 1 PAH","Multimodality Imaging-Based Right Ventricular Phenotyping for Risk Stratification and Short-Term Outcomes in Group 1 Pulmonary Arterial Hypertension: The MIRROR-PAH Study","MIRROR-PAH","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Diagnosis of Group 1 pulmonary arterial hypertension (PAH) according to ESC\u002FERS guidelines\n* Followed at the study center with a diagnosis of PAH\n* Availability of right heart catheterization (RHC) and cardiac magnetic resonance (CMR) imaging data obtained within a clinically relevant time interval\n* Availability of analyzable clinical, imaging, and hemodynamic data\n* Willingness to participate in the study and provision of written informed consent\n\nExclusion Criteria:\n\n* Age younger than 18 years\n* Pulmonary hypertension groups other than Group 1 PAH (Groups 2-5 PH)\n* Absence of either right heart catheterization or cardiac magnetic resonance imaging data within a clinically relevant time interval\n* Incomplete clinical or imaging data preventing analysis\n* Unavailable follow-up data",{"count":154,"type":22},50,"The MIRROR-PAH is a single-center, prospective, observational cohort study evaluating the incremental value of multimodality imaging-derived right ventricular characteristics for risk stratification in patients with Group 1 pulmonary arterial hypertension (PAH). The study aims to determine whether incorporation of echocardiographic and cardiac magnetic resonance (CMR)-derived right ventricular parameters into established non-invasive risk assessment models results in risk reclassification and improves identification of patients at risk for short-term clinical worsening.\n\nAdult patients with established Group 1 PAH undergoing routine follow-up and with available right heart catheterization (RHC) and CMR data will be consecutively enrolled. Clinical, laboratory, echocardiographic, and follow-up data will be prospectively collected over a 6-month period. Associations between multimodality imaging findings, invasive hemodynamic measurements, risk classification, and short-term clinical outcomes will be evaluated.",[28,157,158],"Pulmonary Arterial Hypertension","Right Ventricular Function",[160,161,162,163,164],"pulmonary arterial hypertension","transthoracic echocardiography","cardiac magnetic resonance imaging","right heart catheterization","risk stratification","2026-06-19",{"date":64,"type":36},{"date":168,"type":36},"2026-05-11",{"date":170,"type":22},"2027-05",{"name":172,"class":70},"Istanbul University - Cerrahpasa",{"id":174,"slug":175,"hasResults":12,"nctId":176,"briefTitle":177,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":80,"enrollmentInfo":179,"targetDuration":4,"studyType":23,"phases":180,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":71},"100644352","early-phase-1-percutaneous-pulmonary-artery-denervation-padn-for-the-treatment-of-pulmonary-hypertension-after-transcatheter-mitral-valve-edge-to-edge-repair-m-teer-a-prospective-cohort-study-100644352","NCT07662655","Percutaneous Pulmonary Artery Denervation (PADN) for the Treatment of Pulmonary Hypertension After Transcatheter Mitral Valve Edge-to-Edge Repair (M-TEER): A Prospective Cohort Study","Inclusion Criteria:\n\n1. Age ≥18 years and ≤80 years;\n2. Diagnosed with pulmonary hypertension (defined as mPAP \\>20 mmHg measured by right heart catheterization) at least 3 months after successful M-TEER, having received guideline-directed medical therapy (GDMT) for at least 2 months;\n3. No contraindications for PADN (e.g., anatomical abnormalities of the main pulmonary artery precluding catheter placement, known pulmonary artery stenosis, uncontrolled severe arrhythmias);\n4. Understands and is willing to sign the informed consent form and authorizes the use of health and study-related information;\n5. Willing to comply with the treatment and follow-up schedule required by the protocol\n\nExclusion Criteria:\n\n1. Cardiac index (CI) \\\u003C 1.5 L\u002Fmin\u002Fm²;\n2. Severe renal insufficiency (creatinine clearance rate (CrCL) \\\u003C 30 mL\u002Fmin);\n3. Left ventricular ejection fraction (EF) \\\u003C30% on echocardiography;\n4. Severe hematological disease or severe bleeding tendency (platelet count \\\u003C10×10⁹\u002FL; severe and extensive bleeding; suspected or confirmed intracranial hemorrhage);\n5. Systemic inflammatory disease, malignancy, tricuspid valve stenosis, pulmonary artery stenosis, and other cardiac diseases requiring surgical or interventional treatment;\n6. Acute systemic infectious disease;\n7. Poor general condition due to various systemic diseases;\n8. Pulmonary veno-occlusive disease;\n9. Cachexia;\n10. Diagnosed with WHO Group 1, 3, 4, or 5 pulmonary hypertension;\n11. Anticipated to undergo other surgical or interventional procedures within 6 months;\n12. Life expectancy \\\u003C12 months;\n13. Allergy to the drugs or metal materials used in the study;\n14. Women who are breastfeeding, pregnant, or planning to become pregnant within one year;\n15. Participation in another drug or medical device clinical trial within 3 months prior to screening;\n16. Any condition deemed unsuitable for participation in this clinical trial by the investigator. \\|",{"count":52,"type":22},[181],"EARLY_PHASE1","this study aims to investigate the efficacy and safety of PADN therapy compared with standard medical therapy in patients diagnosed with pulmonary hypertension after M-TEER, thereby providing evidence for clinical treatment decision-making",[28,184],"Pulmonary Hypertension Associated With HFpEF","2026-06-17",{"date":109,"type":36},{"date":188,"type":36},"2026-06-06",{"date":190,"type":22},"2028-08-31",{"name":192,"class":70},"Xiamen Cardiovascular Hospital, Xiamen University",{"id":194,"slug":195,"hasResults":12,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":202,"conditions":203,"keywords":205,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":213,"leadSponsor":215,"locationsCount":217},"100641942","risk-factor-assessment-for-acute-pulmonary-hypertension-crisis-100641942","NCT07653958","Risk Factor Assessment for Acute Pulmonary Hypertension Crisis","Research on the Clinical Risk Factor Assessment System for Acute Pulmonary Hypertension Crisis and Its Mortality","Inclusion Criteria:\n\n* Pulmonary hypertension confirmed by mean pulmonary arterial pressure (mPAP) over 20 mmHg measured by right heart catheter\n* At least once per year of follow-up data collection record\n\nExclusion Criteria:\n\n* Patients with missing baseline or follow-up data\n* Complicated by other diseases with significant influence on survival, such as acute coronary syndrome, malignancy, etc.\n* Complicated by other diseases with significant influence on hemodynamics, such as sepsis, acute left heart failure, and acute pulmonary embolism, etc.\n* Receiving medications with significant influence on hemodynamics",{"count":201,"type":22},5000,"The goal of this observational study is to learn about pulmonary hypertension crisis (PHC) - a severe, and often fatal complication - in patients with pulmonary hypertension (PH). The main questions this study aims to answer are:\n\nWhat are the clinical and hemodynamic features of PHC, and what underlying pathophysiological mechanisms cause it to develop? Can these features be used to diagnostic PHC, predict who is at risk of developing it or dying from it, and develop targeted prevention and treatment of PHC?\n\nA multi-center registry platform and biobank will be established to enroll and follow up patients with PH. Clinical data, hemodynamic measurements, and biological specimen will be collected. Risk prediction and early warning tools of PHC will be developed.",[28,204],"Pulmonary Hypertension Crisis",[206,207,208,209],"Pulmonary hypertension","Pulmonary hypertension crisis","Diagnosis","Risk factor",{"date":211,"type":36},"2026-06-22",{"date":185,"type":36},{"date":214,"type":22},"2029-12-31",{"name":216,"class":70},"Peking Union Medical College Hospital",4,{"id":219,"slug":220,"hasResults":12,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":12,"sex":18,"minAge":226,"maxAge":227,"enrollmentInfo":228,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":230,"conditions":231,"keywords":236,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":71},"100644448","wearable-assessment-of-thoracic-cardiac-health-and-exercise-performance-trial-prospective-100644448","NCT07663799","Wearable Assessment of Thoracic, Cardiac Health and Exercise Performance Trial Prospective","Wearable Assessment of Thoracic, Cardiac Health and Exercise Performance Trial Prospective (WATCH-XP)","WATCH-XP","Inclusion Criteria:\n\n* Age 20 to 70 years old\n* Ability to provide informed consent\n* History of the following cardiovascular conditions:\n* Adult congenital heart disease\n* Pulmonary hypertension\n* Heart failure\n* Coronary artery disease\n* Athletes undergoing cardiovascular assessment\n\nExclusion Criteria:\n\n* Contraindication for undergoing physical exertion including cardio-pulmonary exercise testing (CPX) and 6-minute walk test (6MWT)\n* Pregnancy\n* Known allergy to components of the investigational product","20 Years","70 Years",{"count":229,"type":22},20,"Wearable health technology, particularly smartwatches, has revolutionized personal health monitoring by enabling continuous, non-invasive tracking of various physiological parameters. The potential applications of these devices in cardiology are extensive, but it is crucial to validate their accuracy against established medical-grade devices.\n\nThe Apple Watch Series 9 (Apple, USA) exemplifies the capabilities of modern smartwatches, offering a wide range of health tracking features. These include heart rate monitoring, detection of irregular heart rhythms suggestive of atrial fibrillation, electrocardiogram recording, blood oxygen level measurement, and comprehensive mobility metrics (including VO2 max, six-minute walk distance, walking speed, step length, double support time, and walking asymmetry). Many of these parameters are highly relevant for cardiovascular patients, potentially aiding in disease progression monitoring and adverse event prediction. However, there is a lack of comprehensive validation studies for these devices in specific cardiovascular disease populations.\n\nThis investigator-initiated, prospective observational study will consist of two phases: a training phase which involves 50 participants and a prospective validation phase which involves 20 participants. The study aims to validate smartwatch-based assessments using medical-grade devices and techniques. The study will focus on adult patients with congenital heart disease, pulmonary hypertension, heart failure, and coronary artery disease, as well as athletes undergoing cardiovascular assessment. By comparing smartwatch data with established clinical measurements, we seek to determine the reliability and potential clinical utility of these wearable devices in diverse cardiovascular contexts. Anonymized smartwatch data collected during the two phases will be published to a publicly registry to facilitate further research. This research will help bridge the gap between consumer-grade wearable technology and clinical practice in cardiology.",[232,28,233,234,235],"Congenital Heart Disease","Heart Failure","Coronary Heart Disease (CHD)","Apple Watch",[237,238,239,240,241],"apple watch","congenital heart disease","heart failure","coronary heart disease","pulmonary hypertension","2026-06-16",{"date":109,"type":36},{"date":245,"type":22},"2026-08-01",{"date":247,"type":22},"2028-12-31",{"name":249,"class":70},"The University of Hong Kong",{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":258,"sex":18,"minAge":259,"maxAge":260,"enrollmentInfo":261,"targetDuration":4,"studyType":23,"phases":263,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":267,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":274},"100544776","pulmonary-hypertension-and-oxygen-saturation-targeting-in-preterm-infants-100544776","NCT06373289","Pulmonary Hypertension and Oxygen Saturation Targeting in Preterm Infants","Target Oxygen Saturation Ranges in Infants With Bronchopulmonary Dysplasia Associated Pulmonary Hypertension","PHOX","Inclusion Criteria:\n\n* Between 22w 0\u002F7d and 31w 6\u002F7d gestation at birth\n* Diagnosed with echocardiographic pulmonary hypertension (1) \\>20% flow of blood across the PDA from the pulmonary to arterial circulation, (2) end-systolic flattening of the interventricular septum (eccentricity index \\>1.3), or (3) right ventricular pressure estimates ≥ 35 mm Hg\n* Receiving supplemental oxygen\n* Have mature retinas\n\nExclusion Criteria:\n\n* Major congenital anomalies",true,"1 Month","5 Months",{"count":262,"type":22},39,[25],"Around 50% of infants born extremely preterm develop a chronic lung disease known as bronchopulmonary dysplasia of which some infants will also develop pulmonary hypertension of which 50% of children will die before the age of 2. Physicians are currently limited in their ability to select the most appropriate oxygen targets that will improve outcomes in infants with this condition. This clinical trial will determine whether using different amounts of oxygen improve outcomes in infants with this disease.",[266,28],"Bronchopulmonary Dysplasia",{"date":185,"type":36},{"date":269,"type":22},"2026-07-15",{"date":271,"type":22},"2029-12-01",{"name":273,"class":70},"University of Alabama at Birmingham",2,{"id":276,"slug":277,"hasResults":12,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":258,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":284,"conditions":285,"keywords":286,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":118},"100506361","development-of-an-algorithm-to-detect-pulmonary-hypertension-using-an-electronic-stethoscope-100506361","NCT05873387","Development of an Algorithm to Detect Pulmonary Hypertension Using an Electronic Stethoscope","Deep Learning for Algorithmic Detection of Pulmonary Hypertension Using a Combined Digital Stethoscope and Single-lead Electrocardiogram","Inclusion Criteria:\n\n* Patients, ages \\>18 years, referred for complete 2-dimensional echocardiography or right heart catheterization will be screened for inclusion.\n\nExclusion Criteria:\n\n* Patients undergoing limited echocardiography\n* Intubated patients",{"count":283,"type":22},2420,"The major goal of the study is to determine whether phonocardiography (using the Eko DUO stethoscope which can capture a three lead ECG reading) can present features that relate to the presence of PH diagnosed by echocardiography or right heart catheterization (RHC), and therefore have a potential to assist the provider to suspect PH.",[28],[287,288,289,290],"digital stethoscopes","deep learning","auscultation","electrocardiogram","2026-06-15",{"date":185,"type":36},{"date":294,"type":36},"2023-07-12",{"date":296,"type":22},"2027-05-31",{"name":298,"class":43},"Eko Devices, Inc.",{"id":300,"slug":301,"hasResults":12,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":258,"sex":18,"minAge":19,"maxAge":102,"enrollmentInfo":306,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":308,"conditions":309,"keywords":311,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":319,"completionDateStruct":4,"leadSponsor":321,"locationsCount":71},"100188549","natural-history-study-of-biomarkers-in-pulmonary-arterial-hypertension-100188549","NCT01730092","Natural History Study of Biomarkers in Pulmonary Arterial Hypertension","A Natural History Study of Novel Biomarkers in Pulmonary Arterial Hypertension","* ELIGIBILITY:\n\nThe study will enroll subjects with confirmed and suspected NYHA\u002FWHO Group 1 PH (68) as well as age and sex matched control subjects. Subjects must be at least 18 years of age and must be able to provide informed, written consent for participation in this study. There is no exclusion based on race or sex.\n\nINCLUSION AND EXCLUSION CRITERIA FOR PAH SUBJECTS:\n\nInclusion Criteria:\n\nThe following parameters on RHC are required to meet the hemodynamic definition of PAH (NYHA\u002FWHO Group I PH):\n\n* mean pulmonary artery pressure of \\> 25 mmHg at rest,\n* pulmonary capillary wedge pressure of \\\u003C 15 mmHg (or a left ventricular end-diastolic pressure of \\\u003C 12 mmHg), and\n* pulmonary vascular resistance of \\> 3 Wood units (240 dyn s cm-5).\n\nFor patients with suspected PAH (Group I PH) who have not undergone a RHC and\u002For additional testing to confirm the diagnosis, this testing will be completed as clinically indicated under a procedural consent. If clinically indicated (diagnostic) testing indicates that the subject with suspected PAH does not in fact meet standard criteria for PAH (Group I PH), then the subject will be removed from the study.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women (all women of childbearing potential will be required to have a screening urine or blood pregnancy test)\n* Age less than 18 years\n* Inability to provide informed written consent for participation in the study\n\nINCLUSION AND EXCLUSION CRITERIA FOR HEALTHY CONTROL SUBJECTS:\n\nInclusion Criteria for Control Subjects\n\nAny healthy man or woman who is the appropriate age and sex for matching to a PAH patient\n\n* Must be eligible for MRI and Gadolinium Based MRI studies\n* Must be eligible for CT and Iodine Based Contrast CT studies\n\nExclusion Criteria for Healthy Control Subjects\n\n* Current pregnancy or breastfeeding (All women of childbearing potential will be required to have a screening urine or blood pregnancy test)\n* Electrocardiographic evidence of clinically relevant heart disease\n* Symptoms of coronary or cardiac insufficiency\n* More than one major risk factor for coronary artery disease (excluding age and sex)\n* Obesity (defined as a body mass index \\> 30 kg\u002Fm\\^2)\n* History of underlying conditions\u002Frisk factors associated with pulmonary hypertension such as collagen vascular disease, HIV infection, use of appetite suppressants, chronic liver disease or cirrhosis of the liver, chronic thromboembolic disease, congenital heart defects, hypoxemia and\u002For significant pulmonary parenchymal disease\n* Systemic hypertension that is not well controlled (i.e. blood pressure at the time of screening \\>140\u002F90 mmHg in adults \\\u003C 60 years old or \\>150\u002F90 mmHg in adults 60 years or older) on medications. Subjects taking \\> 2 anti-hypertensive medications will be excluded irrespective of their current blood pressure at time of screening\n* Anemia, thrombocytopenia or coagulopathy\n* Renal insufficiency (defined as an estimated glomerular filtration rate of \\\u003C 60 mL\u002Fmin\u002F1.73m\\^2 of body surface area)\n* Active tobacco use (\\> 6 months) in the past ten years, any tobacco use within 3 months prior to the screening evaluation or any tobacco use prior to completion of the study\n* Inability to provide informed written consent for participation in the study\n* History of recreational drug use with the exception of marijuana (as long as marijuana use was \\> 3 months from the time of study screening).\n\n  * Volunteers may be excluded if in the opinion of the study investigators they have a condition that may adversely affect the outcome of the study or the safety of the volunteer.\n\nExclusion Criteria for MRI in Healthy Control Subjects and Subjects with PAH\n\nThese contraindications include but are not limited to the following devices or conditions:\n\n1. Implanted cardiac pacemaker or defibrillator\n2. Cochlear Implants\n3. Ocular foreign body (e.g. metal shavings)\n4. Embedded shrapnel fragments\n5. Central nervous system aneurysm clips\n6. Implanted neural stimulator\n7. Any implanted device that is incompatible with MRI\n8. Unsatisfactory performance status as judged by the referring physician such that the subject could not tolerate an MRI scan. Examples of medical conditions that would not be accepted would include unstable angina and severe dyspnea at rest\n9. Subjects requiring monitored sedation for MRI studies\n10. Subjects with a condition precluding entry into the scanner (e.g. morbid obesity, claustrophobia, etc.)\n11. Subjects with severe back-pain or motion disorders who will be unable to tolerate supine positioning within the MRI scanner and hold still for the duration of the examination.\n\nExclusion Criteria for Gadolinium Based MRI Studies Only:\n\n1. History of severe allergic reaction to gadolinium contrast agents despite pre- medication with diphenhydramine and prednisone\n2. Chronic kidney disease (an estimated glomerular filtration rate of \\\u003C 60 mL\u002Fmin\u002F1.73m\\^2 of body surface area)\n\nExclusion Criteria for Cardiac Computed Tomography in Healthy Control Subjects and Subjects with PAH:\n\n1\\) Subjects with a condition precluding entry into the scanner (e.g. morbid\n\nobesity, claustrophobia, etc.)\n\nExclusion Criteria for Iodine Based Contrast CTA Studies Only:\n\n1. Serum creatinine \\> 1.4 mg\u002FdL\n2. History of multiple myeloma\n3. Use of metformin-containing products less than 24 hours prior to contrast administration\n4. History of significant allergic reaction to CTA contrast agents despite pre-medication with diphenhydramine and prednisone",{"count":307,"type":22},270,"Background:\n\n\\- High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a rare disorder. Some people have disease-associated PAH and some have PAH from an unknown cause. Researchers want to follow the natural history of all PAH patients to understand how PAH progresses in order to discover targets for future research into new treatments. To further identify treatment targets, they will compare healthy volunteers to patients with PAH.\n\nObjectives:\n\n\\- To study the natural history of PAH.\n\nEligibility:\n\n* Individuals at least 18 years of age who have PAH.\n* Healthy volunteers at least 18 years of age.\n\nDesign:\n\n* Participants with PAH will have periodic visits to the National Institutes of Health Clinical Center. After the first visit, they will return in 6 months and then yearly or every other year for as long as the study continues.\n* The first visit will take up to 3 days. It will involve the following tests:\n* Physical exam and medical history\n* Blood and urine samples\n* Heart and lung function tests and imaging studies\n* Six-minute walk test\n* Questions about exercise and physical activity\n* Healthy volunteers will have only one visit to the Clinical Center, during which they will undergo screening tests, and complete many of the same tests as patients with PAH",[310,28],"Pulmonary Disease",[312,313,158,314,315,316],"Vascular Inflammation","Microarray","Endothelial Dysfunction","Magnetic Resonance Imaging","Natural History","2026-06-13",{"date":242,"type":36},{"date":320,"type":36},"2013-07-15",{"name":116,"class":117},{"id":323,"slug":324,"hasResults":12,"nctId":325,"briefTitle":326,"officialTitle":326,"acronym":327,"eligibilityCriteria":328,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":329,"targetDuration":4,"studyType":23,"phases":331,"briefSummary":332,"conditions":333,"keywords":336,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":355},"100556522","trial-to-evaluate-safety-and-effectiveness-of-mechanical-circulatory-support-in-patients-with-advancing-heart-failure-100556522","NCT06526195","Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure","TEAM-HF","Inclusion Criteria:\n\n1. Subject has provided written informed consent by signing the study Informed Consent Form (ICF) prior to any clinical investigation-related procedure\n2. LVEF ≤30% and Cardiac Index ≤ 2.5 L\u002Fmin\u002Fm²\n3. Limited functional status as demonstrated by 6MWT ≤ 350 m due to HF related reasons OR peak VO2 ≤ 14 mL\u002Fkg\u002Fmin (or \\\u003C50% of predicted peak VO2 value)\n4. NYHA Class IIIB or NYHA Class IV\n5. Subject has ≥ 1 Heart Failure Hospitalization in the last 12 months\n6. Subject is already implanted with a CardioMEMS PA Sensor OR willing to undergo a CardioMEMS PA Sensor implant\n7. Subject is willing and able to be implanted with the HM3 LVAS if randomized to HM3 Group\n\nRandomization Criteria:\n\n1. Subject has been implanted with a CardioMEMS PA Sensor for at least 90 days.\n2. Subject is receiving guideline directed medical therapy with optimal doses (or documented medication contraindication or intolerance) of betablockers, Angiotensin-Converting-Enzyme-inhibitors or Angiotensin II Receptor Blockers or angiotensin receptor neprilysin inhibitor (if eligible), Mineralocorticoid Receptor Antagonists, Sodium-Glucose co-Transporter-2 (SGLT2) inhibitors, and diuretics for at least 30 of the last 90 days.\n3. mean PAP ≥ 30 mmHg.\n4. The subject will not be randomized if they have any other factor that represents inordinate risk for either continued GDMT or LVAD implant.\n\nSingle Arm Registry Criteria:\n\n1. Subject has received a CardioMEMS PA Sensor implant following enrollment in the trial.\n2. Subject is receiving guideline directed medical therapy with optimal doses (or documented medication contraindication or intolerance) of betablockers, Angiotensin-Converting-Enzyme-inhibitors or Angiotensin II Receptor Blockers or angiotensin receptor neprilysin inhibitor (if eligible), Mineralocorticoid Receptor Antagonists, Sodium-Glucose co-Transporter-2 (SGLT2) inhibitors, and diuretics for at least 30 of the last 90 days.\n3. mean PAP \\\u003C30 mmHg\n\nExclusion Criteria:\n\n1. Subject is \\\u003C 18 years of age at the time of informed consent.\n2. Dependent on IV inotrope in the last 30 days.\n3. Contra-indications to HM3 LVAS or CardioMEMS HF system.\n4. Etiology of HF due to or associated with uncorrected thyroid disease, obstructive cardiomyopathy, pericardial disease, amyloidosis, or restrictive cardiomyopathy.\n5. Technical obstacles to LVAD or CardioMEMS implantation which pose an inordinately high surgical risk, in the judgment of the implanter.\n6. Existence of ongoing MCS.\n7. Presence of mechanical aortic valve that will not be either converted to a bioprosthesis or oversewn at the time of LVAD implant.\n8. History of any solid organ transplant.\n9. Psychiatric disease\u002Fdisorder, irreversible cognitive dysfunction or psychosocial issues that are likely to impair compliance with the study protocol and LVAS management.\n10. Presence of an active, uncontrolled infection.\n11. Complex congenital heart disease.\n12. Currently Pregnant or capable of becoming Pregnant and Unwilling to Use Contraception with LVAD.\n13. History of pulmonary embolism within 30 days prior to enrollment or history of recurrent (\\>1 episode) pulmonary embolism and\u002For deep vein thrombosis.\n14. Planned VAD or Bi-VAD support prior to enrollment.\n15. Presence of any one of the following risk factors for or indications of severe end organ dysfunction or failure:\n\n    1. An INR ≥ 2.0 not due to anticoagulation therapy\n    2. An eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m2 and nonresponsive to diuretic therapy or receiving chronic dialysis.\n    3. Biopsy proven liver cirrhosis.\n    4. Need for chronic renal replacement therapy.\n    5. History of severe chronic obstructive pulmonary disease (COPD) defined by Forced Expiratory Volume FEV1 \\\u003C 30% predicted.\n    6. History of cerebrovascular disease with significant (\\> 80%) uncorrected internal carotid stenosis.\n    7. Significant peripheral vascular disease (PVD) accompanied by ischemic rest pain or extremity ulceration.\n16. Any condition other than HF that could limit survival to less than 24 months.\n17. Participation in any other clinical investigation with an active treatment arm that is likely to confound study results or affect the study outcome.",{"count":330,"type":22},850,[25],"The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.",[233,334,335,28],"Heart Diseases","Cardiovascular Diseases",[233,337,338,339,340,341,342,343,344,345],"Left Ventricular Assist Device (LVAD)","Guideline Directed Medical Therapy (GDMT)","Non-inotrope Dependent","Pulmonary Artery Pressure","Hemodynamic Monitoring","Medical Management","CardioMEMS","HeartMate 3 (HM3)","Ambulatory Advanced Heart Failure","2026-06-08",{"date":348,"type":36},"2026-06-10",{"date":350,"type":36},"2024-12-13",{"date":352,"type":22},"2032-09",{"name":354,"class":43},"Abbott Medical Devices",68,{"id":357,"slug":358,"hasResults":12,"nctId":359,"briefTitle":360,"officialTitle":360,"acronym":4,"eligibilityCriteria":361,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":362,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":363,"conditions":364,"keywords":366,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":369,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":376},"100545937","decipher-ild-a-real-world-patient-registry-in-group-3-pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-100545937","NCT06388421","DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)","Inclusion Criteria:\n\n1. Adults aged 18 years or older\n2. Diagnosis of fibrotic ILD based on high-resolution computed tomography imaging, including but not limited to:\n\n   1. Idiopathic interstitial pneumonia, including idiopathic pulmonary fibrosis\n   2. Autoimmune ILD\n   3. Chronic hypersensitivity pneumonitis\n   4. Nonspecific interstitial pneumonia\n   5. Occupational lung disease\n   6. Combined pulmonary fibrosis and emphysema with fibrosis greater than the extent of emphysema on lung imaging as determined by the Investigator\n3. For patients to be eligible for Cohorts 1 to 3: RHC confirmed PH (mean pulmonary artery pressure \\>20 mmHg, pulmonary artery wedge pressure\n\n   ≤15 mmHg, pulmonary vascular resistance \\>2 WU).\n4. For patients to be eligible for Cohort 1, they must not be receiving inhaled treprostinil at Baseline.\n5. For patients to be eligible for Cohort 2, they must have initiated\n\nTyvaso\u002FTyvaso DPI at 1 of the following time points:\n\n1. Baseline\n2. ≤90 days prior to Baseline 6. For patients to be eligible for Cohort 3, they must be receiving Tyvaso\u002FTyvaso DPI at Baseline and for \\>90 days prior to Baseline. 7. For patients to be eligible for Cohort 4: Prior RHC not meeting the definition of PH as described in Inclusion Criterion 3 but has a pulmonary artery wedge pressure ≤15 mmHg. 8. Co-enrollment in other observational or interventional studies is permitted. 9. Patient is willing and able to provide informed consent and complete surveys\u002Fquestionnaires in English or Spanish.\n\nExclusion Criteria:\n\n1. Confirmed diagnosis of Group 1, 2, 4, or 5 PH\n\n   a. In cases in which a patient has a diagnosis of PH-ILD along with a concomitant diagnosis of another PH group (eg, Group 1), enrollment may be permitted at the Investigator's discretion if, in their clinical judgment, PH-ILD is the predominant driver of the patient's PH.\n2. Confirmed diagnosis of Group 3 PH associated with lung diseases and or hypoxia other than fibrotic ILD, as outlined in Inclusion Criterion 2.\n3. Patients receiving inhaled treprostinil (Yutrepia™) at Baseline. Patients receiving other forms of PH therapy will be eligible for enrollment.",{"count":21,"type":22},"This is a prospective, real world, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and interstitial lung disease (ILD).",[365,28,86],"Pulmonary Hypertension Due to Lung Diseases and Hypoxia",[241,367,368],"interstitial lung disease","pulmonary hypertension associated with interstitial lung disease",{"date":348,"type":36},{"date":371,"type":36},"2025-01-23",{"date":373,"type":22},"2030-11-30",{"name":375,"class":43},"United Therapeutics",67,{"id":378,"slug":379,"hasResults":12,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":4,"eligibilityCriteria":383,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":384,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":385,"conditions":386,"keywords":389,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":71},"100642262","pulmonary-artery-pressure-in-predicting-pulmonary-embolism-in-patients-presenting-to-the-emergency-department-with-dyspnea-100642262","NCT07641400","Pulmonary Artery Pressure in Predicting Pulmonary Embolism in Patients Presenting To The Emergency Department With Dyspnea","The Diagnostic Value of The Difference Between Prior and Immediate Pulmonary Artery Pressure in Predicting Pulmonary Embolism in Patients Presenting To The Emergency Department With Dyspnea","Inclusion Criteria:\n\n* Presenting to the emergency department with dyspnea between the specified dates,\n* Being 18 years of age or older,\n* Being evaluated in the emergency department with a preliminary diagnosis of pulmonary embolism,\n* Having a recorded pulmonary artery pressure measurement at the time of hospital admission,\n* Having a previous pulmonary artery pressure measurement in the patient's records,\n* Having sufficient and complete clinical, laboratory, imaging, and echocardiography data available for the study.\n\nExclusion Criteria:\n\n* Patients under 18 years of age,\n* Lack of pulmonary artery pressure data from the time of emergency admission or from the previous period,\n* Lack of necessary clinical, laboratory, or imaging data for pulmonary embolism evaluation,\n* In cases of repeated admissions for the same patient, only the first suitable admission will be considered; other admissions will be excluded from the study,\n* Patients whose data is unavailable in the record system or whose data is insufficient to be analyzed for research purposes.Inclusion Criteria for the Study",{"count":82,"type":22},"The aim of this study is to determine the usability of echocardiographic PAP changes obtained from emergency department records in the early risk stratification of pulmonary embolism.",[387,28,388],"Emergency Department Patients","Pulmonary Embolism",[390,241,391,392,393],"emergency deparment patients","pulmonary embolism","dispnea","chest pain",{"date":395,"type":36},"2026-06-11",{"date":397,"type":22},"2026-06-01",{"date":399,"type":22},"2026-10-01",{"name":401,"class":70},"Antalya Health Sciences University",{"id":403,"slug":404,"hasResults":12,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":408,"eligibilityCriteria":409,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":410,"targetDuration":4,"studyType":23,"phases":412,"briefSummary":414,"conditions":415,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":420,"startDateStruct":422,"completionDateStruct":423,"leadSponsor":425,"locationsCount":71},"100638552","phase-2-effect-of-vasopressin-versus-norepinephrine-on-post-operative-mean-pulmonary-arterial-pressure-following-pulmonary-endarterectomy-surgery-100638552","NCT07614438","Effect of Vasopressin Versus Norepinephrine on Post-operative Mean Pulmonary Arterial Pressure Following Pulmonary Endarterectomy Surgery,","Effect of Vasopressin Versus Norepinephrine on Post-operative Mean Pulmonary Arterial Pressure Following Pulmonary Endarterectomy Surgery, a Randomized Open Label Trial","VANOPE","Inclusion Criteria:\n\n* Age ≥18 years;\n* Patient scheduled for pulmonary endarterectomy surgery;\n* In women of childbearing potential: negative serum pregnancy test and use of adequate contraception;\n* Affiliation to the French social care service;\n* Patient able to understand and sign a written informed consent form.\n\nExclusion Criteria:\n\n* Emergency surgery;\n* Mesenteric ischemia and\u002For acute coronary syndrome within the month preceding the intervention;\n* Patients with documented mesenteric artery stenosis;\n* Impossibility to insert the pulmonary artery catheter (anatomical or technical issue);\n* Preoperative administration of norepinephrine and\u002For inotropic drugs (dobutamine, isoproterenol, epinephrine) or patients assisted by veno-venous or veno-arterial ECMO before surgery;\n* Known allergy to the active substance vasopressin or to any of its excipients;\n* Concomitant coronary bypass procedure or other combined surgery (i.e. valve replacement);\n* mPAP\\\u003C25 mmHg on preoperative right heart catheterization;\n* Patient with preoperative natremia below 130 mol\u002FL;\n* Patient participating to another interventional clinical trial;\n* For females only: documented pregnancy or lactation;\n* Patient under tutorship, curatorship or legal protection;\n* Patient deprived of liberty.",{"count":411,"type":22},90,[413],"PHASE2","Chronic thromboembolic pulmonary hypertension (CTEPH), one of the leading causes of pulmonary hypertension (PH), is caused by the chronic obstruction of the pulmonary arteries following episode of pulmonary embolism. It is the only cause of PH which is accessible to a potential curative surgical treatment: the pulmonary endarterectomy (PEA). Because of their underlying disease (pulmonary hypertension and potential right heart dysfunction), anesthesia should be performed cautiously. Perioperative hemodynamic management often requires the administration of a vasopressor to maintain the arterial pressure above a specific threshold of 65 mmHg.\n\nLow dose of vasopressin increases systemic arterial pressure with minimal effects on the pulmonary circulation. This profile suggests that vasopressin may be an ideal agent for vasopressor support in the high-risk population of patients with pulmonary hypertension.\n\nTo date, there is no data on the use of vasopressin in patient undergoing PEA surgery. The interesting properties of vasopressin - specifically, its ability to increase systemic arterial resistance while having a low impact on pulmonary resistance and offering potential renal protective effects - are highly advantageous in the specific subset of patient scheduled for PEA.\n\nThe investigators aim to conduct a randomized single center open label study to compare the effect of vasopressin compared to norepinephrine on mean pulmonary artery pressure after PEA surgery.\n\nThe primary objective of this study is to determine whether the use of vasopressin compared to norepinephrine decrease the mean pulmonary artery pressure after PEA surgery.\n\nParticipation to the study involves follow up at day 30 following surgery.",[416,28,417,418],"Anesthesia","Chronic Pulmonary Thromboembolism","Vasopressor","2026-05-29",{"date":421,"type":36},"2026-06-02",{"date":245,"type":22},{"date":424,"type":22},"2028-09-01",{"name":426,"class":70},"Fondation Hôpital Saint-Joseph",{"id":428,"slug":429,"hasResults":12,"nctId":430,"briefTitle":431,"officialTitle":431,"acronym":4,"eligibilityCriteria":432,"healthyVolunteers":12,"sex":18,"minAge":433,"maxAge":4,"enrollmentInfo":434,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":436,"conditions":437,"keywords":441,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":447,"completionDateStruct":448,"leadSponsor":450,"locationsCount":71},"100637681","a-comparison-of-a-medication-adherence-platform-fortiskap-vs-usual-care-in-subjects-on-oral-medications-for-the-treatment-of-interstitial-lung-disease-sarcoid-and-pulmonary-hypertension-100637681","NCT07613216","A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary Hypertension","Inclusion Criteria:\n\n1. 21 years of age or older at time of enrollment\n2. Primary diagnosis of interstitial lung disease (including sarcoidosis) AND\u002FOR pulmonary hypertension\n3. Currently managing their oral medications independently (i.e., without requiring caregiver administration)\n4. At least one oral medication with a primary indication for treatment of ILD or PH already in use, or planned for initiation with insurance approval secured, at the time of enrollment\n5. 6-Minute Walk Test (6MWT) scheduled within the next 30 days or performed within the past 30 days\n6. For ILD subjects: FVC and\u002For DLCO scheduled within the next 30 days or performed within the past 90 days\n7. For PH subjects: Cardiac echocardiography scheduled within the next 30 days or performed within the past 90 days\n8. Daily access to a smartphone compatible with the FORTISKAP™ companion application\n9. Proficient in English\n\nExclusion Criteria:\n\nFailure to meet any one of the above inclusion criteria","21 Years",{"count":435,"type":22},100,"This study will evaluate whether participants with serious lung diseases such as idiopathic pulmonary fibrosis, sarcoidosis, and pulmonary hypertension who use the FORTISKAP™ smart medication cap - a bottle-top device that tracks prescription bottle openings and sends dose reminders to participants and their care team - take their medications more consistently and experience better health outcomes compared to similar participants receiving standard care without the device. Participation requires no changes to prescribed medications, testing or clinical visits beyond what is already part of routine care; participants use a modified medication bottle equipped with the FORTISKAP™ cap for nine months.",[438,439,28,440],"Idiopathic Pulmonary Fibrosis (IPF)","Sarcoidosis Lung","Usual Interstitial Pneumonia",[442,86,443,444],"medication adherence","nintedanib","pirfenidone","2026-05-26",{"date":419,"type":36},{"date":140,"type":22},{"date":449,"type":22},"2027-08",{"name":451,"class":43},"Cosmos Rx, Inc",{"id":453,"slug":454,"hasResults":12,"nctId":455,"briefTitle":456,"officialTitle":457,"acronym":458,"eligibilityCriteria":459,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":460,"targetDuration":4,"studyType":23,"phases":462,"briefSummary":464,"conditions":465,"keywords":466,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":467,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":475},"100606732","phase-3-efficacy-and-safety-study-of-treprostinil-palmitil-inhalation-powder-tpip-in-participants-with-pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-100606732","NCT07179380","Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)","A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease","PALM-ILD","Inclusion Criteria\n\n* Diagnosis of PH World Health Organisation (WHO) Group 3 associated with ILD \\[including but not limited to idiopathic interstitial pneumonia (IIP), chronic hypersensitivity pneumonitis (HSP), connective tissue disease-associated interstitial lung disease (CTD-ILD), combined pulmonary fibrosis and emphysema (CPFE)\\].\n* Confirmation of fibrotic interstitial lung disease by centrally overread computed tomography (CT) scan performed at Screening or within prior 12 months.\n* PH confirmed by right heart catheterization (RHC) at Screening or within 12 months prior to Screening, with the following hemodynamic findings:\n\n  * Mean pulmonary arterial pressure (mPAP) \\>20 millimetre of mercury (mmHg) and\n  * Pulmonary capillary wedge pressure (PCWP) of ≤15 mmHg and\n  * Pulmonary vascular resistance (PVR) ≥4 wood units (WU).\n* 6 Minute walking distance (6MWD) ≥100 and ≤500 meters at two 6MWTs at Screening performed at least 4 hours apart, with the difference between the 2 distances ≤15%.\n* Participants receiving chronic medication for underlying disease (e.g., antifibrotic, immunomodulators, immunosuppressants, etc.) and\u002For phosphodiesterase 5 (PDE5) inhibitors, should be on this treatment for ≥90 days and on a stable dose for ≥30 days prior to Screening.\n* Capable of giving signed informed consent as described in Section 10.1.5 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n\nExclusion criteria\n\n* Diagnosis of Pulmonary Hypertension WHO Groups 1, 2, 4, or 5, or subtypes of PH WHO Group 3 other than interstitial lung disease.\n* Primary diagnosis of chronic obstructive pulmonary disease (COPD) and\u002For forced expiratory volume in 1 second (FEV1)\u002FFVC \\\u003C0.7 (based on screening or historical spirometry within the prior 6 months).\n* Clinically significant left heart disease:\n\n  * evidence of clinically significant left-sided valvular heart disease,\n  * left ventricular failure with left ventricular ejection fraction (LVEF) \\\u003C45%, or diagnosis of heart failure with preserved ejection fraction (HFpEF)\n  * echocardiography findings at Screening suggestive for postcapillary PH\n  * unstable ischemic heart disease\n  * unstable arrhythmia, including uncontrolled atrial fibrillation (rate-controlled arrhythmia or paroxysmal atrial fibrillation is allowed)\n* Evidence of chronic thromboembolic disease or recent (within 6 months of Screening) acute pulmonary embolism.\n* Known hypersensitivity or contraindication to treprostinil or TPIP or TPIP formulation excipients (e.g., mannitol, leucine).\n* Current use of cigarettes or e-cigarettes: An adult who has smoked at least 100 cigarettes in his or her lifetime and who currently smokes either every day or some days.\n* Current use of inhaled marijuana, recreational or medical (current use defined as used at least one or more times during the past 30 days prior to Screening) or expected use during the study.\n* Any other medical or psychological condition including relevant laboratory abnormalities at Screening that, in the opinion of the Investigator, suggest a new and\u002For insufficiently understood disease and\u002For may present an unreasonable risk to the study participant as a result of his\u002Fher participation in this clinical trial, may impede their ability complete the study or the study assessments or confound the outcomes of the trial.\n\nNote: Other protocol defined inclusion\u002Fexclusion criteria may apply.",{"count":461,"type":22},344,[463],"PHASE3","The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with PH-ILD.",[28,86],[241,367],{"date":468,"type":36},"2026-05-27",{"date":470,"type":36},"2026-01-07",{"date":472,"type":22},"2028-12-30",{"name":474,"class":43},"Insmed Incorporated",109,{"id":477,"slug":478,"hasResults":12,"nctId":479,"briefTitle":480,"officialTitle":481,"acronym":4,"eligibilityCriteria":482,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":483,"targetDuration":4,"studyType":23,"phases":484,"briefSummary":485,"conditions":486,"keywords":487,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":490,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":495,"locationsCount":4},"100610934","phase-3-an-open-label-extension-study-of-treprostinil-palmitil-inhalation-powder-tpip-in-participants-with-pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-100610934","NCT07234032","An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)","A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease","Inclusion Criteria\n\n* Participants who have completed the lead-in PH-ILD TPIP Study INS1009-311 (NCT07179380).\n* Capable of giving signed informed consent that includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n* Agree not to participate in any other interventional trials or use investigational drugs or devices while participating in the INS1009-312 study.\n\nExclusion Criteria\n\n* Participants who experienced any adverse events (AEs) evaluated as causally related to TPIP by the Investigator in a lead-in study, which in the opinion of the Investigator, could pose an unreasonable risk of continued treatments for the participant.\n* Current use or expected need for pulmonary arterial hypertension (PAH)-approved therapy, including prostacyclin, prostacyclin analogues or other prostacyclin receptor agonists, endothelin receptor antagonists, and\u002For soluble guanylate cyclase stimulator, or any PH-ILD approved treprostinil therapy. Use of phosphodiesterase 5 inhibitors in line with applicable guidelines is allowed.\n* Diagnosis of Pulmonary Hypertension World Health Organisation (WHO) Groups 1, 2, 4, or 5, or subtypes of PH WHO Group 3 other than interstitial lung disease (including combined pulmonary fibrosis and emphysema).\n* Evidence of left ventricular failure, heart failure with preserved ejection fraction (HFpEF) or postcapillary PH.\n* Known hypersensitivity or contraindication to treprostinil or TPIP or TPIP formulation excipients (eg, mannitol, leucine).\n\nNote: Other protocol-defined inclusion\u002Fexclusion criteria may apply.",{"count":461,"type":22},[463],"The primary objective of this study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-311 (NCT07179380).",[28,86],[488],"pulmonary hypertension, interstitial lung disease","2026-05-21",{"date":445,"type":36},{"date":492,"type":22},"2026-06-05",{"date":494,"type":22},"2031-01-22",{"name":474,"class":43},{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":4,"eligibilityCriteria":502,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":503,"targetDuration":4,"studyType":23,"phases":505,"briefSummary":506,"conditions":507,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":508,"lastUpdatePostDateStruct":509,"startDateStruct":511,"completionDateStruct":513,"leadSponsor":515,"locationsCount":517},"100598617","phase-2-a-study-to-learn-about-the-study-medicine-called-pf-07868489-in-people-with-pulmonary-arterial-hypertension-who-have-previously-participated-in-a-clinical-study-with-pf-07868489-100598617","NCT07073820","A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489","A PHASE 2, OPEN-LABEL EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF PF-07868489 ADMINISTERED TO ADULT PARTICIPANTS WITH PULMONARY ARTERIAL HYPERTENSION","This study is seeking participants who are:\n\n* aged 18 years or older at screening of the previous study and completed the required treatment duration with PF-07868469 and other assessments at the end of that study.\n* willing and able to abide with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.\n* do not have worsening or hospitalization for worsening PAH during the qualifying study.\n* not on placement for a surgery to replace any tissue or part of the body (transplant), and planned surgery for PAH.\n* do not have an ongoing major health issue in the qualifying study, which in the opinion of the study doctor could make the participant not qualify for this study.\n* not suffering from or in the past have suffered from hepato-pulmonary syndrome (liver-related lung problem).\n* not currently prescribed or taking medicines called as GLP-1 agonist.",{"count":504,"type":22},36,[413],"The purpose of this study is to learn about the long-term safety, tolerability and effects of the study medicine (PF-07868489) for the possible treatment of PAH. PAH is a condition in which there is high blood pressure in the arteries that carry blood from the heart to the lungs. This high pressure makes it harder for the heart to pump blood through those lungs, potentially damaging the right side of the heart.\n\nThis is an open-label study. Which means that both the healthcare providers and the study participants are aware of the medicine being given. This study is also an extension study with study medicine (PF-07868489). An extension study allows patients from an earlier clinical study (also called as qualifying study) to continue participating to assess long-term benefits and safety of the medicine.",[28],"2026-05-18",{"date":510,"type":36},"2026-05-19",{"date":512,"type":36},"2025-11-10",{"date":514,"type":22},"2028-07-18",{"name":516,"class":43},"Pfizer",48,{"id":519,"slug":520,"hasResults":12,"nctId":521,"briefTitle":522,"officialTitle":523,"acronym":524,"eligibilityCriteria":525,"healthyVolunteers":12,"sex":18,"minAge":526,"maxAge":527,"enrollmentInfo":528,"targetDuration":4,"studyType":23,"phases":529,"briefSummary":530,"conditions":531,"keywords":534,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":544,"lastUpdatePostDateStruct":545,"startDateStruct":547,"completionDateStruct":549,"leadSponsor":551,"locationsCount":554},"100511316","phase-2-breathe-easier-with-tadalafil-therapy-for-dyspnea-in-copd-ph-100511316","NCT05937854","Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH","Effect of PDE5 Inhibitor on Respiratory Symptoms in COPD Complicated by Pulmonary Hypertension","BETTER COPD-PH","Inclusion Criteria:\n\n1. Outpatients with COPD, defined as airflow limitation with post-bronchodilator obstruction on baseline visit spirometry, identified by FEV1\u002FFVC \\\u003C 70% or \\\u003C the lower limit of normal (5th percentile of a normal population based on Global Lung Function Initiative reference equations), OR any emphysema on chest CT noted in a clinical radiology report confirmed by study investigator review.\n2. Eligible subjects must have PH documented as follows:\n\n   1. Main Pulmonary Artery\u002FAscending Aorta (PA\u002FA) diameter \\> 0.90 on clinically available CT scans within 12 months OR\n   2. Main Pulmonary Artery diameter \\> 30.8mm on clinically available CT scans within 12 months OR\n   3. outpatient echocardiography done within 6 months of enrollment demonstrating PA sys \\> 34 mmHg OR\n   4. Mean Pulmonary Artery Pressure \\> 20 on Right Heart Catheterization done within 6 months of enrollment and when Veteran is clinically stable.\n3. Eligible subjects must be dyspneic, as quantitated by a score of at least 20 on the baseline UCSD Shortness of Breath Questionnaire, assessed at the time of the baseline visit.\n4. Treatment with at least one long-acting bronchodilator for at least 4 weeks, assessed at the time of the baseline visit by chart review and patient interview.\n5. Age 35-89 Years\n6. Women of childbearing potential must meet one of the following criteria for the previous three months AND must have a negative pregnancy test on the day of testing. If more than 36 hours since the participant's last pregnancy test, they will be tested again at the study visit.\n\n   1. have been using a contraceptive measure (an intrauterine device (IUD), a contraceptive implant, oral contraceptives, barrier methods, or abstinence)\n   2. have a male partner with a vasectomy\n   3. have a tubal ligation procedure or a medical diagnosis (such as infertility) or therapies\u002Fprocedures that precludes pregnancy (such as cancer treatments or endometrial ablation)\n   4. are in a same-sex relationship\n   5. have a male partner not capable of fathering children because of congenital anomalies, other surgery, or medical treatment\n7. Women who are not considered to be of childbearing potential who have been surgically sterilized (for example: removal of ovaries or fallopian tubes, or hysterectomy) or are post-menopausal (no menstrual period for more than 6 months).\n\nExclusion Criteria:\n\n1. Diagnosis of PH in the following subgroups of the updated WHO Clinical Classification:\n\n   1. Group 1 (Idiopathic, heritable, drug- or toxin-induced, Pulmonary Arterial Hypertension associated with connective tissue disease, congenital heart disease)\n   2. Group 2 (left atrial hypertension)\n   3. Group 3 PH not attributable to COPD\n   4. Group 4 (chronic thromboembolic PH) or other forms of PH not associated with primary lung disease.\n2. Systemic hypotension in the ambulatory setting (at least 3 reproducible measurements of systolic BP \\\u003C89 mmHg, recorded by a health care provider over 1 week).\n3. Moderate or severe hepatic impairment (Child-Pugh B and C).\n4. Severe renal insufficiency (GFR \\\u003C30 ml\u002Fmin\u002F1.73 m2)\n5. Echocardiography within 6 months showing greater than moderate aortic stenosis (aortic valve area \\\u003C1.0 cm2), greater than moderate mitral regurgitation, or diastolic dysfunction (Any two of the following: Average E\u002Fe' \\>14, Septal e' velocity \\\u003C 7 or lateral e' velocity \\\u003C10, LA volume index \\> 34 ml\u002Fm2). LVEF \\\u003C 50%. Any aortic or mitral valve replacement.\n6. Any acute or chronic impairment (other than dyspnea) that limits ability to comply with the study requirements.\n7. Current unstable angina, myocardial infarction or stroke within 6 months.\n8. Requirement for nitrate therapy for any clinical indication.\n9. Active prescription for a PDE-5 inhibitor or other pulmonary vasodilator other than oxygen as a PH treatment.\n10. History of the following retinal disorders: retinitis pigmentosa, non-arteritic anterior ischemic optic neuropathy, or crowded optic disc noted on ophthalmology examinations recorded in CPRS.\n11. Contraindications: PDE-5i allergy, penile anatomical deformations, sickle cell anemia, multiple myeloma, leukemia, bleeding disorders, active peptic ulcer disease, retinitis pigmentosa or other retinal disorders listed above. In accordance with 38 USC 7332, this information will be kept confidential and will not be disclosed in presentations, publications, or any other dissemination of the study results, or to anyone outside of the IRB-approved study team.\n12. Use of any of the following: rifampin, systemic anti-fungal azole agents, protease inhibitors, phenobarbital, dilantin.\n13. Pregnant, possibly pregnant by report, or if breastfeeding. If found to be pregnant at the study visit, the study visit will not be conducted.\n14. Pulmonary veno-occlusive disease\n15. Hypoxia (reproducible ambulatory SaO2 \\\u003C 90% on supplemental oxygen at rest recorded by a health care provider over 1 week).\n16. Diagnosis of Obstructive Sleep Apnea without a prescription for treatment.\n17. Newly prescribed (less than 4 weeks duration) bronchodilator or diuretic therapy or new enrollment in pulmonary rehabilitation at the time of Baseline.\n18. Students, VA employees, persons with impaired decision making, illiterate and non-English speakers, and terminally ill patients.\n19. COPD or CHF exacerbation within the past 4 weeks.\n20. On-going therapy with doxazosin.\n\nWomen of childbearing potential must have a documented negative pregnancy test and must be using adequate contraception during the study and for 9 months afterward. Monthly pregnancy tests will be done, and compliance with contraception use will be documented at the telephone and clinic visits. Should a female become pregnant at any time during the study, the study medication will be discontinued.\n\nDoxazosin use will be defined as current active prescription and usage of Doxazosin or planned trial (pending prescription) of Doxazosin for treatment of benign prostatic hypertrophy, systemic hypertension, or other indication. A list of alpha-1 antagonists (ex. prazosin, doxazosin, tamulosin, terazosin, etc.) will be included in the patient study medication handout to prompt the patient to avoid any new usage of these drugs during the trial period. On-going therapy with doxazosin is an exclusion criterion due to greater risk of hypotension.","35 Years","89 Years",{"count":5,"type":22},[413],"The investigators will study whether the drug tadalafil improves shortness of breath in 126 Veterans with Chronic Obstructive Pulmonary Disease (COPD) and high blood pressure in the lungs. The investigators will also assess whether tadalafil improves quality of life, home daily physical activity, exercise endurance, the frequency of acute flares of COPD, blood pressure in the lungs, and lung function. Veterans who enroll in the trial will be allocated by chance to either active tadalafil or an inactive identical capsule (placebo). Neither the Veteran nor the investigator will know whether the Veteran is taking tadalafil or placebo. Veterans will be followed closely in clinic or by telephone at 1, 2, 3, 4, 5, and 6 months, with attention to side effects and safety. At 1,3, and 6 months the investigators will repeat the questionnaires and testing of blood pressures in the lung and lung function. The investigators anticipate that the results of this study will determine whether tadalafil improves shortness of breath when added to usual medications for COPD.",[532,28,533],"Chronic Obstructive Pulmonary Disease","Dyspnea",[535,536,537,538,539,540,541,542,543],"COPD","cigarette smoke","lung","echocardiography","chest CT","physical activity","spirometry","dyspnea","clinically important deterioration","2026-05-14",{"date":546,"type":36},"2026-05-15",{"date":548,"type":36},"2024-04-01",{"date":550,"type":22},"2029-03-01",{"name":552,"class":553},"VA Office of Research and Development","FED",5,{"id":556,"slug":557,"hasResults":12,"nctId":558,"briefTitle":559,"officialTitle":559,"acronym":560,"eligibilityCriteria":561,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":562,"targetDuration":4,"studyType":23,"phases":564,"briefSummary":565,"conditions":566,"keywords":567,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":570,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":575,"locationsCount":71},"100603151","understanding-the-effects-of-pulmonary-arterial-hypertension-on-lean-muscle-mass-100603151","NCT07132788","Understanding the Effects of Pulmonary Arterial Hypertension on Lean Muscle Mass","MUSCLE UP-PH","Inclusion Criteria:\n\n* Signed informed consent prior to initiation of any study mandated procedure.\n* Diagnosis of PAH belonging to one of the following subgroups of Group 1 PH according to the updated clinical classification \\[Humbert 2022\\]\n\n  * Idiopathic (IPAH)\n  * Heritable (HPAH)\n  * Drugs or toxins induced\n  * Associated (APAH) with one of the following:\n\n    * Connective tissue disease;\n    * Human immunodeficiency virus (HIV) infection;\n    * Congenital heart disease; or\n    * Portopulmonary hypertension\n* Diagnosis of PAH within 6 months of enrollment or diagnosis of PAH and on stable therapy for 3 months prior to enrollment\n* Documented hemodynamic diagnosis of PAH by right heart catheterization (RHC), prior to enrollment showing:\n\n  * mPAP \\> 20 mmHg; and\n  * PAWP or LVEDP ≤ 15 mmHg\n  * PVR \\> 2 Wood units\n\nExclusion Criteria:\n\n* Prior to enrollment, evidence of moderately severe obstructive ventilator defect with:\n\n  * FEV1\u002FFVC ≤ 5th percentile; and\n  * FEV1 z-score \\\u003C 2.5\n* Prior to enrollment, evidence of severe restrictive defect with\n\n  * TLC \\\u003C 5th percentile\n  * FEV1 z-score \\\u003C 4\n* Prior to enrollment, hospitalization (within 1 week) for decompensated right heart failure\n* More than moderate aortic or mitral valve disease\n* LVEF \\\u003C 40% within 1 year of screening\n* Pregnancy",{"count":563,"type":22},150,[25],"Patients with pulmonary arterial hypertension (PAH) are at increased risk of muscle loss and decreased physical activity. This study will aim to (1) understand the way in which muscle loss occurs in PAH, particularly the role of fat surrounding the heart, and (2) look at the impact muscle loss has on quality of life, daily physical activity, and hospitalizations in patients with PAH. The findings from this study could help identify potentially treatable factors that may improve the overall quality of life and physical functioning of patients with PAH.\n\nSubjects will be asked to attend a baseline visit where the following will be performed:\n\n* Measure your vital signs\n* Undergo a research blood draw, less than 4 tablespoons\n* Provide a urine pregnancy test (if applicable)\n* Review demographics, personal history, and medical history\n* Review current PAH medications\n* Complete questionnaires on how your PAH affects you\n* Complete a test of physical performance\n* Complete a grip strength test\n* Undergo an echocardiogram (Echo)\n* Complete a six-minute walk test\n* Undergo a Chest CT Scan\n* Undergo a scan of your body composition (DXA scan)\n* Obtain a weight and body composition measurement on the InBody Scale Subjects will also complete activity moniotring, two 24-hour diet recalls, and participate in remote follow-up visits every 6 months",[28],[241,568],"body composition","2026-05-07",{"date":168,"type":36},{"date":572,"type":36},"2025-05-01",{"date":574,"type":22},"2029-09-30",{"name":576,"class":70},"University of Pennsylvania",{"id":578,"slug":579,"hasResults":12,"nctId":580,"briefTitle":581,"officialTitle":582,"acronym":583,"eligibilityCriteria":584,"healthyVolunteers":12,"sex":18,"minAge":585,"maxAge":4,"enrollmentInfo":586,"targetDuration":4,"studyType":23,"phases":587,"briefSummary":588,"conditions":589,"keywords":593,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":597,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":603,"locationsCount":71},"100640872","right-ventricular-response-to-exercise-among-patients-with-chronic-obstructive-pulmonary-disease-100640872","NCT07576894","Right Ventricular Response to Exercise Among Patients With Chronic Obstructive Pulmonary Disease","Phenotyping Resting and Exertional Right Ventricular Dysfunction Among Patients With Chronic Obstructive Pulmonary Disease","ReV UP COPD","Inclusion Criteria:\n\n* COPD (determined by ratio of forced expiratory volume in 1 second to forced vital capacity \\[FEV1\u002FFVC\\] \\\u003C0.7)\n* Age \\>= 40 years\n\nExclusion Criteria:\n\n* Exacerbation of COPD in the 3 months prior to enrollment\n* Change in COPD therapy in the 3 weeks prior to enrollment\n* Requirement of \\>6 LPM supplemental oxygen at rest\n* Requirement of \\>10 LPM supplemental oxygen with exertion\n* Active\u002Funcontrolled cardiovascular disease (e.g. hypertension with blood pressure \\>150\u002F100 despite antihypertensives; coronary artery disease with angina; left ventricular ejection fraction ≤40%; uncontrolled arrhythmia; pulmonic, mitral or aortic valvular abnormality greater than mild in severity; tricuspid regurgitation greater than moderate in severity)\n* Volume overload (jugular vascular distension or greater than trace peripheral edema)\n* World Health Organization Functional Class IV\n* Known pulmonary hypertension with mean pulmonary artery pressure \\>45 mmHg\n* Untreated severe obstructive sleep apnea and\u002For obesity hypoventilation syndrome\n* Active malignancy (other than skin)\n* Medical conditions that limit exercise on an upright stationary bicycle (e.g. severe osteoarthritis, imbalance\u002Fgait instability, etc.)\n* Pregnancy\n* Body mass index \\\u003C18 or \\>35\n* Hematocrit \\\u003C25% or \\>55%\n* For subset undergoing right heart catheterization, chronic anticoagulation that is unable to be held for the study visit\n* For subset undergoing right heart catheterization or exercise training, forced expiratory volume in 1 second of \\\u003C20%\n* For exercise training, already engaged in routine exercise training (\\>30 minutes at \\>3 METs 3 times\u002Fweek or more)\n* For exercise training, inability to complete initial in-person exercise training sessions for approximately 35 minutes 3x\u002Fweek for 3 weeks (followed by exercise training sessions with an option for hybrid remote\u002Fin-person participation)\n* For exercise training with an option for hybrid remote exercise training, any medical conditions which threaten the safety of remote exercise training (e.g. imbalance\u002Fgait instability, etc.).","40 Years",{"count":52,"type":22},[25],"This study plans to learn more about heart function among individuals with chronic obstructive pulmonary disease (COPD). In particular, the investigators want to understand the different patterns of right ventricular response during rest and moderate- vs high-intensity exercise. By identifying patterns of right ventricular dysfunction, this study will help identify better treatments for patients with COPD in the future.",[535,28,590,591,592],"Exercise","Right Ventricular (RV) Dysfunction","Exercise Training",[535,206,590,594,595],"Pulmonary rehabilitation","Exercise training","2026-05-04",{"date":598,"type":36},"2026-05-08",{"date":600,"type":36},"2025-08-01",{"date":602,"type":22},"2030-08-01",{"name":604,"class":70},"University of Colorado, Denver",{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":582,"officialTitle":582,"acronym":4,"eligibilityCriteria":609,"healthyVolunteers":12,"sex":18,"minAge":585,"maxAge":4,"enrollmentInfo":610,"targetDuration":4,"studyType":23,"phases":611,"briefSummary":612,"conditions":613,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":615,"startDateStruct":616,"completionDateStruct":618,"leadSponsor":620,"locationsCount":71},"100508144","phenotyping-resting-and-exertional-right-ventricular-dysfunction-among-patients-with-chronic-obstructive-pulmonary-disease-100508144","NCT05896579","Inclusion Criteria:\n\n* COPD (determined by ratio of forced expiratory volume in 1 second to forced vital capacity \\[FEV1\u002FFVC\\] \\\u003C0.7)\n* Age \\>= 40 years\n\nExclusion Criteria:\n\n* Exacerbation of COPD in the 3 months prior to enrollment\n* Change in COPD therapy in the 3 weeks prior to enrollment\n* Requirement of \\>6 LPM supplemental oxygen at rest\n* Requirement of \\>10 LPM supplemental oxygen with exertion\n* Active\u002Funcontrolled cardiovascular disease (e.g. hypertension with blood pressure \\>150\u002F100 despite antihypertensives; coronary artery disease with angina; left ventricular ejection fraction ≤40%; arrhythmia; pulmonic, mitral or aortic valvular abnormality greater than mild in severity; tricuspid regurgitation greater than moderate in severity)\n* Volume overload (jugular vascular distension or greater than trace peripheral edema)\n* World Health Organization Functional Class IV\n* Known pulmonary hypertension with mean pulmonary artery pressure \\>45 mmHg\n* Untreated severe obstructive sleep apnea or obesity hypoventilation syndrome\n* Active malignancy (other than skin)\n* Medical conditions that limit exercise on an upright stationary bicycle (e.g. severe osteoarthritis, imbalance\u002Fgait instability, etc.)\n* Pregnancy\n* Body mass index \\\u003C18 or \\>40\n* Hematocrit \\\u003C25% or \\>55%\n* For invasive CPET, chronic anticoagulation that is unable to be held for the study visit\n* For invasive CPET, forced expiratory volume in 1 second of \\\u003C20%",{"count":52,"type":22},[25],"This study plans to learn about heart function among individuals with chronic obstructive pulmonary disease (COPD). In particular, the investigators want to understand the different patterns of right ventricular response during rest and moderate- vs high-intensity exercise. By identifying patterns of right ventricular dysfunction, this study will help identify better treatments for patients with COPD in the future.",[535,28,614,590,592],"Right Ventricular Dysfunction",{"date":598,"type":36},{"date":617,"type":36},"2023-08-22",{"date":619,"type":22},"2030-08",{"name":604,"class":70},{"id":622,"slug":623,"hasResults":12,"nctId":624,"briefTitle":625,"officialTitle":625,"acronym":4,"eligibilityCriteria":626,"healthyVolunteers":258,"sex":18,"minAge":627,"maxAge":4,"enrollmentInfo":628,"targetDuration":4,"studyType":23,"phases":630,"briefSummary":632,"conditions":633,"keywords":638,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":640,"lastUpdatePostDateStruct":641,"startDateStruct":643,"completionDateStruct":645,"leadSponsor":647,"locationsCount":71},"100410437","phase-1-hyperpolarized-129xe-mr-imaging-of-lung-function-in-healthy-volunteers-and-subjects-with-pulmonary-disease-100410437","NCT04624490","Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease","Inclusion Criteria:\n\nHealthy Volunteers:\n\n* Subject has no diagnosed pulmonary conditions\n* Ability to read and understand English or Spanish\n\nSubjects with Lung Disease:\n\n* Subject has a diagnosis of pulmonary dysfunction made by a physician\n* No acute worsening of pulmonary function in the past 30 days\n* Ability to read and understand English or Spanish\n\nExclusion Criteria:\n\n* MRI is contraindicated based on responses to MRI screening questionnaire\n* Subject is pregnant or lactating\n* Subject does not fit into 129Xe vest coil used for MRI\n* Subject cannot hold his\u002Fher breath for 15-16 seconds\n* Subject deemed unlikely to be able to comply with instructions during imaging\n* Oxygen saturation \\\u003C88% on room air or with supplemental oxygen\n* Cognitive deficits that preclude ability to provide consent\n* Institutionalization","3 Years",{"count":629,"type":22},260,[631],"PHASE1","The purpose of this study is to develop and evaluate the usefulness of hyperpolarized (HP) 129Xe gas MRI for regional assessment of pulmonary function.",[634,535,86,635,28,636,637],"Asthma","Cystic Fibrosis","Pulmonary Infection","Other Lung Disease",[639],"Hyperpolarized 129Xe MRI","2026-04-30",{"date":642,"type":36},"2026-05-06",{"date":644,"type":36},"2020-11-02",{"date":646,"type":22},"2028-10-26",{"name":648,"class":70},"Mario Castro, MD, MPH"]